Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial to investigate VDA-1102 for the treatment of actinic keratosis (AK), an early form of cutaneous squamous cell carcinoma (cSCC)

Next Previous
Trial Profile

A clinical trial to investigate VDA-1102 for the treatment of actinic keratosis (AK), an early form of cutaneous squamous cell carcinoma (cSCC)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tuvatexib (Primary)
  • Indications Actinic keratosis
  • Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

  • 29 Jun 2016 Status changed from recruiting to completed, according to a Vidac Pharma media release.
  • 17 May 2016 New trial record
  • 25 Feb 2016 Status changed from planning to recruiting, according to a Vidac Pharma media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top